Clinical Research Papers:
Jie-du granule preparation for the treatment of advanced hepatocellular carcinoma: a retrospective cohort study of 177 patients
Metrics: PDF 967 views | HTML 1121 views | ?
L.Y. Chen1, X.F. Zhai1,*, Z. Chen1, J.F. Zhu2, P.A. Qian2, H.T. Zhao1 and C.Q. Ling1
1 Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China
2 Department of Liver Disease, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China
* These authors have contributted equally to this work
C.Q. Ling, email:
Keywords: hepatocellular carcinoma, Jie-du granule, best supportive treatment, retrospective cohort study
Received: July 28, 2016 Accepted: October 19, 2016 Published: October 25, 2016
Objective: To compare the clinical efficacy of Jie-du granule preparation versus best supportive treatment in patients with advanced hepatocellular carcinoma.
Methods: A retrospective cohort study was carried out in patients with advanced liver cancer. Patients were divided into Jie-du granule treatment (JD) and best supportive treatment (BST) groups. The main outcomes included median overall survival time.
Results: A total of 177 patients with Barcelona Clinic Liver Cancer stage C receiving JD granule treatment or BST were enrolled between January 2012 and December 2014. The overall median survival time was 6.2 months (95% confidence interval [CI] 4.546-7.854) in the JD group versus 4 months (95% CI 3.471-4.529) in the BST group. Significant independent risk factors were alpha-fetoprotein (P = 0.048), Child-Pugh class (P = 0.005), vascular invasion (P = 0.003), and extrahepatic metastasis (P = 0.0018). For patients with two or fewer of these independent risk factors, the overall median survival of those treated with JD was significantly longer than that of patients receiving BST (P < 0.05).
Conclusion: Jie-du granule preparation may prolong survival of patients with advanced HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.